New Mechanism for Treatment of Schizophrenia

Video

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.

To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see here.

Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Related Videos
nicotine use
brain schizophrenia
schizophrenia
schizophrenia
exciting, brain
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
Related Content
Here are highlights from the week in Psychiatric Times.

The Week in Review: April 15-19

April 20th 2024
Article
Treating ‘Morally Objectionable’ Patients

Treating ‘Morally Objectionable’ Patients

September 27th 2021
Podcast
Researchers investigated the effects of this supplementation on cognitive function and disease severity in schizophrenia. Here’s what they found.

Study Finds That Probiotics, Vitamin D May Enhance Cognitive Function in Schizophrenia

April 12th 2024
Article
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

May 11th 2021
Podcast
What is new in research on schizophrenia?

Schizophrenia Research Roundup: April 12, 2024

April 12th 2024
Article
Here are some updates from the world of psychiatry throughout the month of March.

Psychiatry in the News: March 2024

March 29th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.